These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

221 related articles for article (PubMed ID: 32280231)

  • 21. Diagnosis of neuronal ceroid lipofuscinosis type 2 (CLN2 disease): Expert recommendations for early detection and laboratory diagnosis.
    Fietz M; AlSayed M; Burke D; Cohen-Pfeffer J; Cooper JD; Dvořáková L; Giugliani R; Izzo E; Jahnová H; Lukacs Z; Mole SE; Noher de Halac I; Pearce DA; Poupetova H; Schulz A; Specchio N; Xin W; Miller N
    Mol Genet Metab; 2016 Sep; 119(1-2):160-7. PubMed ID: 27553878
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ongoing retinal degeneration despite intraventricular enzyme replacement therapy with cerliponase alfa in late-infantile neuronal ceroid lipofuscinosis type 2 (CLN2 disease).
    Dulz S; Schwering C; Wildner J; Spartalis C; Schuettauf F; Bartsch U; Wibbeler E; Nickel M; Spitzer MS; Atiskova Y; Schulz A
    Br J Ophthalmol; 2023 Oct; 107(10):1478-1483. PubMed ID: 35772852
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Enzyme replacement therapy delays pupillary light reflex deficits in a canine model of late infantile neuronal ceroid lipofuscinosis.
    Whiting RE; Narfström K; Yao G; Pearce JW; Coates JR; Castaner LJ; Jensen CA; Dougherty BN; Vuillemenot BR; Kennedy D; O'Neill CA; Katz ML
    Exp Eye Res; 2014 Aug; 125():164-72. PubMed ID: 24954537
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Managing CLN2 disease: a treatable neurodegenerative condition among other treatable early childhood epilepsies.
    Mazurkiewicz-Bełdzińska M; Del Toro M; Haliloğlu G; Huidekoper HH; Kravljanac R; Mühlhausen C; Andersen BN; Prpić I; Striano P; Auvin S
    Expert Rev Neurother; 2021 Nov; 21(11):1275-1282. PubMed ID: 33538188
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Clinical Pharmacokinetics and Pharmacodynamics of Cerliponase Alfa, Enzyme Replacement Therapy for CLN2 Disease by Intracerebroventricular Administration.
    Kim A; Grover A; Hammon K; de Hart G; Slasor P; Cherukuri A; Ajayi T; Jacoby D; Schulz A; Specchio N; de Los Reyes E; Gissen P; Henshaw JW
    Clin Transl Sci; 2021 Mar; 14(2):635-644. PubMed ID: 33202105
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Immunogenicity to cerliponase alfa intracerebroventricular enzyme replacement therapy for CLN2 disease: Results from a Phase 1/2 study.
    Cherukuri A; Cahan H; de Hart G; Van Tuyl A; Slasor P; Bray L; Henshaw J; Ajayi T; Jacoby D; O'Neill CA; Schweighardt B
    Clin Immunol; 2018 Dec; 197():68-76. PubMed ID: 30205177
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Development of the "Hamburg Best Practice Guidelines for ICV-Enzyme Replacement therapy (ERT) in CLN2 Disease" Based on 6 Years Treatment Experience in 48 Patients.
    Schwering C; Kammler G; Wibbeler E; Christner M; Knobloch JK; Nickel M; Denecke J; Baehr M; Schulz A
    J Child Neurol; 2021 Jul; 36(8):635-641. PubMed ID: 33543660
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Management Strategies for CLN2 Disease.
    Williams RE; Adams HR; Blohm M; Cohen-Pfeffer JL; de Los Reyes E; Denecke J; Drago K; Fairhurst C; Frazier M; Guelbert N; Kiss S; Kofler A; Lawson JA; Lehwald L; Leung MA; Mikhaylova S; Mink JW; Nickel M; Shediac R; Sims K; Specchio N; Topcu M; von Löbbecke I; West A; Zernikow B; Schulz A
    Pediatr Neurol; 2017 Apr; 69():102-112. PubMed ID: 28335910
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Cerebrospinal fluid neurofilament light chain levels in CLN2 disease patients treated with enzyme replacement therapy normalise after two years on treatment.
    Iwan K; Patel N; Heslegrave A; Borisova M; Lee L; Bower R; Mole SE; Mills PB; Zetterberg H; Mills K; Gissen P; Heywood WE
    F1000Res; 2021; 10():614. PubMed ID: 35106137
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Intravitreal enzyme replacement for inherited retinal diseases.
    Rodriguez-Martinez AC; Wawrzynski J; Henderson RH
    Curr Opin Ophthalmol; 2024 May; 35(3):232-237. PubMed ID: 38170785
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Exploring concurrent validity of the CLN2 Clinical Rating Scale: Comparison to PedsQL using cerliponase alfa clinical trial data.
    Specchio N; Gissen P; de Los Reyes E; Olaye A; Camp C; Curteis T; Griffiths A; Butt T; Cohen-Pfeffer J; Slasor P; Sisic Z; Jain M; Schulz A
    PLoS One; 2024; 19(5):e0302382. PubMed ID: 38776275
    [TBL] [Abstract][Full Text] [Related]  

  • 32. CLN2 Disease (Classic Late Infantile Neuronal Ceroid Lipofuscinosis).
    Kohlschütter A; Schulz A
    Pediatr Endocrinol Rev; 2016 Jun; 13 Suppl 1():682-8. PubMed ID: 27491216
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Natural History Studies in NCL and Their Expanding Role in Drug Development: Experiences From CLN2 Disease and Relevance for Clinical Trials.
    Nickel M; Schulz A
    Front Neurol; 2022; 13():785841. PubMed ID: 35211079
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Multifocal retinopathy in Dachshunds with CLN2 neuronal ceroid lipofuscinosis.
    Whiting RE; Pearce JW; Castaner LJ; Jensen CA; Katz RJ; Gilliam DH; Katz ML
    Exp Eye Res; 2015 May; 134():123-32. PubMed ID: 25697710
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Clinical management and diagnosis of CLN2 disease: consensus of the Brazilian experts group.
    Sampaio LPB; Manreza MLG; Pessoa A; Gurgel-Giannetti J; Coan AC; Júnior HVL; Embiruçu EK; Henriques-Souza AMM; Kok F
    Arq Neuropsiquiatr; 2023 Mar; 81(3):284-295. PubMed ID: 37059438
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Current and Emerging Treatment Strategies for Neuronal Ceroid Lipofuscinoses.
    Kohlschütter A; Schulz A; Bartsch U; Storch S
    CNS Drugs; 2019 Apr; 33(4):315-325. PubMed ID: 30877620
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Visual perception and macular integrity in non-classical CLN2 disease.
    Atiskova Y; Wildner J; Wibbeler E; Nickel M; Spitzer MS; Schwering C; Schulz A; Dulz S
    Graefes Arch Clin Exp Ophthalmol; 2022 Nov; 260(11):3693-3700. PubMed ID: 35652945
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Evolution of Movement Disorders in Patients With CLN2-Batten Disease Treated With Enzyme Replacement Therapy.
    Spaull R; Soo AK; Batzios S; Footitt E; Whiteley R; Mink JW; Carr L; Gissen P; Kurian MA
    Neurology; 2024 Aug; 103(3):e209615. PubMed ID: 38976822
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Neuronal ceroid lipofuscinosis type 2: an Australian case series.
    Johnson AM; Mandelstam S; Andrews I; Boysen K; Yaplito-Lee J; Fietz M; Nagarajan L; Rodriguez-Casero V; Ryan MM; Smith N; Scheffer IE; Ellaway C
    J Paediatr Child Health; 2020 Aug; 56(8):1210-1218. PubMed ID: 32329550
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    ; ; . PubMed ID:
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.